106 related articles for article (PubMed ID: 27614754)
1. Residual FDG uptake of primary thyroid lymphoma after treatment may overestimate residual lymphoma.
Fujii H; Nakadate M; Tanaka H; Harata N; Oota S; Isogai J; Yoshida K
Ann Nucl Med; 2016 Dec; 30(10):756-759. PubMed ID: 27614754
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
3. Is 18F-FDG PET/CT useful for distinguishing between primary thyroid lymphoma and chronic thyroiditis?
Nakadate M; Yoshida K; Ishii A; Koizumi M; Tochigi N; Suzuki Y; Ryu Y; Nakagawa T; Umehara I; Shibuya H
Clin Nucl Med; 2013 Sep; 38(9):709-14. PubMed ID: 23816945
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT for assessing therapy response in primary thyroid lymphoma.
Lin EC
Clin Nucl Med; 2007 Feb; 32(2):152-3. PubMed ID: 17242576
[No Abstract] [Full Text] [Related]
6. Thyroid incidentaloma identified by ¹⁸F-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance.
Pagano L; Samà MT; Morani F; Prodam F; Rudoni M; Boldorini R; Valente G; Marzullo P; Baldelli R; Appetecchia M; Isidoro C; Aimaretti G
Clin Endocrinol (Oxf); 2011 Oct; 75(4):528-34. PubMed ID: 21575027
[TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose positron emission tomography in primary thyroid lymphoma with coexisting lymphocytic thyroiditis.
Arabi M; Dvorak R; Smith LB; Kujawski L; Gross MD
Thyroid; 2011 Oct; 21(10):1153-6. PubMed ID: 21875367
[TBL] [Abstract][Full Text] [Related]
8. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
9. Thyroid incidentalomas discovered on positron emission tomography CT scanning - Malignancy rate and significance of standardised uptake values.
Brindle R; Mullan D; Yap BK; Gandhi A
Eur J Surg Oncol; 2014 Nov; 40(11):1528-32. PubMed ID: 24915858
[TBL] [Abstract][Full Text] [Related]
10. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
11. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
[TBL] [Abstract][Full Text] [Related]
12. The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas.
Yoshio K; Sato S; Okumura Y; Katsui K; Takemoto M; Suzuki E; Katayama N; Kaji M; Kanazawa S
Clin Nucl Med; 2011 Feb; 36(2):113-7. PubMed ID: 21220972
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
14. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
[TBL] [Abstract][Full Text] [Related]
15. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
16. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
17. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
18. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
[TBL] [Abstract][Full Text] [Related]
20. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
